FP
IRWD icon

Foundry Partners’s Ironwood Pharmaceuticals IRWD Stock Holding History

Foundry Partners’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-254,177
Closed -$1.66M – 317
2024
Q2 		$1.66M Buy
254,177
+13,604
+6% +$96.2K 0.09% 206
2024
Q1 		$2.1M Buy
+240,573
New +$2.92M 0.11% 199
2023
Q3 		– Sell
-481,902
Closed -$5.13M – 316
2023
Q2 		$5.13M Buy
481,902
+26,487
+6% +$285K 0.31% 91
2023
Q1 		$4.79M Buy
455,415
+24,640
+6% +$276K 0.3% 99
2022
Q4 		$5.34M Buy
430,775
+75,725
+21% +$859K 0.29% 85
2022
Q3 		$3.68M Buy
355,050
+37,824
+12% +$429K 0.23% 117
2022
Q2 		$3.66M Buy
317,226
+57,283
+22% +$675K 0.22% 123
2022
Q1 		$3.27M Sell
259,943
-567,790
-69% -$6.51M 0.17% 173
2021
Q4 		$9.65M Sell
827,733
-65,337
-7% -$802K 0.34% 116
2021
Q3 		$11.7M Buy
+893,070
New +$11.5M 0.42% 90

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Foundry Partners's IRWD Position: Q3 2024 in Review

Foundry Partners sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2024, closing a stake of 254,177 shares — an estimated $1.66M sold.

Foundry Partners first reported a position in IRWD in Q3 2021 and held it in 10 quarters. The position peaked at $11.7M in Q3 2021. 221 funds tracked by Wall St. Rank hold IRWD as of Q3 2024.

  • Foundry Partners reported no remaining Ironwood Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Foundry Partners sold 254,177 Ironwood Pharmaceuticals shares in Q3 2024, an estimated $1.66M.
  • Foundry Partners first reported a position in Ironwood Pharmaceuticals in Q3 2021 and held it in 10 quarters.
  • Foundry Partners's Ironwood Pharmaceuticals position peaked at $11.7M in Q3 2021.
  • 221 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2024.

Based on Foundry Partners's 13F filing for Q3 2024, filed 8 Nov 2024.